The DOI matches its Crossref record; 80 of the 81 references it cites were found in a registry or an index.
LSD enhances suggestibility in healthy volunteers
Abstract
Rationale Lysergic acid diethylamide (LSD) has a history of use as a psychotherapeutic aid in the treatment of mood disorders and addiction, and it was also explored as an enhancer of mind control. Objectives The present study sought to test the effect of LSD on suggestibility in a modern research study. Methods Ten healthy volunteers were administered with intravenous (i.v.) LSD (40-80 μg) in a within-subject placebo-controlled design. Suggestibility and cued mental imagery were assessed using the Creative Imagination Scale (CIS) and a mental imagery test (MIT). CIS and MIT items were split into two versions (A and B), balanced for 'efficacy' (i.e. A ≈ B) and counterbalanced across conditions (i.e. 50 % completed version 'A' under LSD). The MIT and CIS were issued 110 and 140 min, respectively, post-infusion, corresponding with the peak drug effects. Results Volunteers gave significantly higher ratings for the CIS (p = 0.018), but not the MIT (p = 0.11), after LSD than placebo. The magnitude of suggestibility enhancement under LSD was positively correlated with trait conscientiousness measured at baseline (p = 0.0005). Conclusions These results imply that the influence of suggestion is enhanced by LSD. Enhanced suggestibility under LSD may have implications for its use as an adjunct to psychotherapy, where suggestibility plays a major role. That cued imagery was unaffected by LSD implies that suggestions must be of a sufficient duration and level of detail to be enhanced by…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The first study, which was limited by a small sample of 10 healthy volunteers, showed that LSD (40–80 µg, i.v.) enhances suggestibility on the Creative Imagination Scale, while Cued Imagery remained unaffected (83).”
From Modulation of Social Cognition via Hallucinogens and “Entactogens” (2019) · cites this paper as [83]
Citations
Cites
An inventory for measuring depression
BECK, A. T. (1961) · Archives of General Psychiatry · doi:10.1001/archpsyc.1961.01710120031004 · Cited by 38,032
Selective Cortical Undercutting As a Means of Modifying and Studying Frontal Lobe Function in Man
Scoville, W. B. (1949) · Journal of neurosurgery · doi:10.3171/jns.1949.6.1.0065 · Cited by 7,374
Validation of the five-factor model of personality across instruments and observers.
McCrae, R. R., & Costa, P. T. (1987) · Journal of Personality and Social Psychology · doi:10.1037/0022-3514.52.1.81 · Cited by 6,404
Tellegen, A., & Atkinson, G. (1974) · Journal of Abnormal Psychology · doi:10.1037/h0036681 · Cited by 2,196
Carhart-Harris, R. L., Leech, R., Hellyer, P. J., Shanahan, M., Feilding, A., Tagliazucchi, E., Chialvo, D. R., & Nutt, D. (2014) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2014.00020 · Cited by 1,252
Self-citationNichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206
Human hallucinogen research: guidelines for safety
Johnson, M., Richards, W., & Griffiths, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108093587 · Cited by 1,203
Gasser, P., Holstein, D., Michel, Y., Doblin, R., Yazar-Klosinski, B., Passie, T., & Brenneisen, R. (2014) · Journal of Nervous & Mental Disease · doi:10.1097/nmd.0000000000000113 · Cited by 750
Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents
Glennon, R. A., Titeler, M., & MCKENNEY, J. D. J. (1984) · Life Sciences · doi:10.1016/0024-3205(84)90436-3 · Cited by 635
Research works printed but not linked: 2
- Grof S (1980) LSD Psychotherapy. Hunter House, US
- Weitzenhoffer AM, Hilgard ER (1959) Stanford hypnotic susceptibility scale, for use in research investigations in the field of hypnotic phenomena. Consulting Psychologists, Palo Alto
Cited by
Sorted by citations
Items 301–319 of 319
Psychédéliques et psychanalyse : du cadre thérapeutique aux potentialités symboligènes
Rabeyron, T., & Artru, E. (2026) · In Analysis · doi:10.1016/j.inan.2026.100577
Predictors of the Effectiveness of Psychedelics in Treating Depression—A Scoping Review
Chmiel, J., & Rybakowski, F. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27052202 · Cited by 1
The Phenomenology of Psychedelic Experiences
Pavăl, D. (2026) · SpringerBriefs in religious studies · doi:10.1007/978-3-032-20214-7_2
Carhart-Harris, R. L., Zeifman, R. J., Pasquini, L., Nandi, B., Rohani-Shukla, C., Suseelan, S., Mediano, P. A. M., Rosas, F. C. W., Timmermann, C., Kettner, H., et al. (2026) · Frontiers in Neuroscience · doi:10.3389/fnins.2026.1875339
Self-citationWießner, I., Falchi-Carvalho, M., Laborde, S., Barros, H., Bolcont, R., Gurgel, M. M. M., Mograbi, D. C., Coelho, N., Palhano-Fontes, F., & de Araujo, D. (2026) · Research Square · doi:10.21203/rs.3.rs-9640916/v1
Speech markers of psychological change following a psychedelic 5-MeO-DMT retreat
Kuc, J., McAlpine, R. G., Sellers, A., Blackburne, G., Lametti, D. R., & Skipper, J. I. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261443690
Market approval and the right to health: a human rights perspective on MDMA-assisted therapy
Bublitz, C. (2026) · JME Practical Bioethics · doi:10.1136/jmepb-2025-000039
Simonsson, O., Hendricks, P. S., Osika, W., & Goldberg, S. B. (2026) · Psychedelic Medicine · doi:10.1177/28314425261444135
Averill, L. A., & Neitzke‐Spruill, L. (2026) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20260006
Cellular mechanisms of serotonergic psychedelics - apical hypercontextualisation
Kaup, K., Jiménez, J. H., & Aru, J. (2026) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2026.106876
Dames, S., Williams, K., Campbell, A., Taylor, W., Harder, M., Gagnon, M., Manson, G., & Kryskow, P. (2026) · Journal of Evaluation in Clinical Practice · doi:10.1111/jep.70556
Jurlando, C. (2026) · Psychedelics · doi:10.1016/j.psyche.2026.100037
Cognitive neuroscience of hypnosis
Lanfranco, R. C., & Terhune, D. B. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-29258-3.00030-6
Norris, J. J., & Holoyda, B. J. (2026) · Psychiatry Psychology and Law · doi:10.1080/13218719.2026.2718113
Psychedelics and suicidality: A double-edged sword - risks, mechanisms, and moving forward
Mallevays, M., & Berkovitch, L. (2026) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2026.113878
Simon, G., Hopper, J. W., Cherniak, A. D., Cassidy, E. K., Skragge, M., & Granqvist, P. (2026) · Neuroethics · doi:10.1007/s12152-026-09672-2
Psychedelic tourism as a structured precision field: A predictive-processing framework
Zhang, W., & Zhang, F. (2026) · Journal of Psychedelic Studies · doi:10.1556/2054.2026.00538
Set and Setting Beyond Reductionism: A Response to Patch and Smith
Hartogsohn, I., Pronovost-Morgan, C., & Ramaekers, J. G. (2026) · Neuroethics · doi:10.1007/s12152-026-09678-w
Metadata
- Authors
- Carhart-Harris, R. L., Kaelen, M., Whalley, M. G., Bolstridge, M., Feilding, A., & Nutt, D. J.
- Affiliations
- Imperial College London (GB)
- Royal Berkshire NHS Foundation Trust (GB)
- Beckley Foundation (GB)
- Corresponding author
- Carhart-Harris, R. L.
- Venue
- Psychopharmacology
- Published
- 2014-09-23
- Volume
- 232
- Issue
- 4
- Pages
- 785-794
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- OpenAlex
- W2037317432
- Cited by
- 320
- References
- 81
- Citations by year
- 2026: 25 · 2025: 40 · 2024: 52 · 2023: 36 · 2022: 40 · 2021: 38 · 2020: 19 · 2019: 13 · 2018: 18 · 2017: 15 · 2016: 18 · 2015: 4 · 2014: 1
- FWCI
- 14.95
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Wellcome Trust
- Beckley Foundation
- National Institute for Health and Care Research
- Medical Research Council (MR/J00460X/1)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Life Sciences › Neuroscience › Cognitive Neuroscience › Pain Management and Placebo Effect
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- lysergic acid diethylamide, LSD, suggestibility, psychedelic effects, mind control, psychotherapy adjunct
- MeSH terms
- Adult, Affect, Dose-Response Relationship, Drug, Hallucinogens, Humans, Imagination, Infusions, Intravenous, Lysergic Acid Diethylamide, Male, Placebos, Suggestion, Single-Blind Method, Healthy Volunteers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review